A hapvida (HAPV3) was, by far, the action of the Ibovespa which fell the most in March. In the month, the health insurance staged highly volatile trading sessions, even dropping more than 30% in a single day.
With the closing of this Friday (31), the company’s shares ended March with a fall of 41.65%. There was a large discrepancy in relation to the second stock with the biggest drop on the Ibovespa, which fell “only” 21.20%.
Company | ticker | Change in March (%) |
---|---|---|
hapvida | HAPV3 | -41.65 |
Qualicorp | WHICH3 | -21.2 |
3R Petroleum | RRRP3 | -19.06 |
Rede D’Or | RDOR3 | -16.87 |
Arezzo | ARZZ3 | -14.87 |
But what happened to Hapvida to lead this month’s losses ranking?
The problem
To understand why investors are abandoning the company’s thesis, it is necessary to remember that the results of the fourth quarter of 2022 were very poorly received by the market.
The trading session following the balance sheet saw the collapse of more than 30% of the operator’s shares, which reversed the profit (disregarding adjustments) and presented a loss of R$ 316.7 million.
What worries investors is Hapvida’s cash burn. They try to understand the company’s ability to unlock cash under regulatory rules, which would solve its current cash flow problem. solvency.
In a report published in the month, the Itaú BBA explains that most of the company’s debt is allocated to the holding company, while the “true” cash generators are the operating subsidiaries.
Regulatory rules applicable to operators (which is where the real money is) prevent distributions to holding companies if the required minimum cash holdings are not met, which serves as a kind of regulatory guarantee. It is due to the excess of cash that the subsidiaries are able to transfer money to their holding company, the most conventional form being the payment of dividends to the controller.
As a rule, operators need a minimum solvency margin (capital) to get through periods of uncertainty. The issue is that Hapvida’s cash deterioration due to the challenging macroeconomic scenario ended up leading to an accelerated deterioration in the company’s capital adequacy.
“It is important to understand that this is a question of regulatory capital, not that there is a lack of money – a fact seen with relief by some investors that we heard in recent days”, emphasizes the BBA.
recent shot
This week, the company’s shares soared more than 18% in the trading session on Tuesday (28). The movement took place after the announcement that the company engaged the banks Bank of America Merrill Lynch, UBS Brazil, BTG Pactual and the Itaú BBA to analyze the feasibility and structure a potential common stock offering.
In addition, Hapvida announced the sale and lease of 10 properties owned by the company for a total amount of R$ 1.25 billion.
O Santander even assessed that the operations have the potential to improve investor sentiment in relation to Hapvida, reducing concerns related to leverage and regulatory solvency.
On Tuesday, the Bradesco BBI raised Hapvida’s recommendation from “neutral” to “buy”, with a target price of BRL 4.20.
According to BBI, assuming the R$ 2.1 billion in cash (from property sales) and capital increase (follow-on), net debt (reported at the end of 2022, outside IFRS 16 standards) drops 30 % to R$4.9 billion, equivalent to 2.5x Ebitda (pro-forma, outside IFRS 16 standards) of R$2.066 billion (of 3.4x) adjusting R$106 million in rent expenses.
That is, leverage, one of the main points of concern for the company, may gain a relief of 0.9%.
O JPMorgan, in turn, updated the recommendation for the company’s shares, also to “buy”, highlighting the company’s liquidity situation.
Source: Moneytimes

I am an author and journalist with a focus on market news. I have worked for a global news website for the past two years, writing articles on a range of topics relating to the stock market. My work has been published in international publications and I have delivered talks at both academic institutions and business conferences around the world.